- Home
- BBIO vs COKE Comparison
BBIO vs COKE Comparison
Compare BBIO & COKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- COKE
- Stock Information
- Founded
- BBIO 2015
- COKE 1902
- Country
- BBIO United States
- COKE United States
- Employees
- BBIO N/A
- COKE N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- COKE Beverages (Production/Distribution)
- Sector
- BBIO Health Care
- COKE Consumer Staples
- Exchange
- BBIO Nasdaq
- COKE Nasdaq
- Market Cap
- BBIO 9.4B
- COKE 10.0B
- IPO Year
- BBIO 2019
- COKE N/A
- Fundamental
- Price
- BBIO $55.32
- COKE $119.82
- Analyst Decision
- BBIO Strong Buy
- COKE
- Analyst Count
- BBIO 16
- COKE 0
- Target Price
- BBIO $64.44
- COKE N/A
- AVG Volume (30 Days)
- BBIO 2.0M
- COKE 641.5K
- Earning Date
- BBIO 11-11-2025
- COKE 10-29-2025
- Dividend Yield
- BBIO N/A
- COKE 0.83%
- EPS Growth
- BBIO N/A
- COKE 24.05
- EPS
- BBIO N/A
- COKE 6.71
- Revenue
- BBIO $235,812,000.00
- COKE $6,947,643,000.00
- Revenue This Year
- BBIO $115.46
- COKE N/A
- Revenue Next Year
- BBIO $65.03
- COKE N/A
- P/E Ratio
- BBIO N/A
- COKE $17.87
- Revenue Growth
- BBIO 7.62
- COKE 3.22
- 52 Week Low
- BBIO $21.72
- COKE $105.21
- 52 Week High
- BBIO $55.32
- COKE $146.09
- Technical
- Relative Strength Index (RSI)
- BBIO 59.91
- COKE 58.00
- Support Level
- BBIO $52.97
- COKE $118.02
- Resistance Level
- BBIO $55.13
- COKE $121.52
- Average True Range (ATR)
- BBIO 1.58
- COKE 2.19
- MACD
- BBIO 0.16
- COKE 0.42
- Stochastic Oscillator
- BBIO 84.41
- COKE 91.34
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About COKE Coca-Cola Consolidated Inc.
Coca-Cola Consolidated Inc distributes, markets and manufactures nonalcoholic beverages. It offer a range of nonalcoholic beverage products and flavors, including both sparkling and still beverages. Sparkling beverages are carbonated beverages and the Company's principal sparkling beverage is Coca Cola. Still beverages include energy products and noncarbonated beverages such as bottled water, ready-to-drink tea, ready-to-drink coffee, enhanced water, juices and sports drinks. The Company has three operating segments: Nonalcoholic Beverages, All Other and Eliminations. key revenue is generated from Nonalcoholic Beverages.